Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 4
2005 3
2006 6
2007 7
2008 11
2009 17
2010 20
2011 17
2012 18
2013 24
2014 15
2015 22
2016 24
2017 24
2018 22
2019 19
2020 25
2021 25
2022 20
2023 18
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

293 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.
Vos JL, Elbers JBW, Krijgsman O, Traets JJH, Qiao X, van der Leun AM, Lubeck Y, Seignette IM, Smit LA, Willems SM, van den Brekel MWM, Dirven R, Baris Karakullukcu M, Karssemakers L, Klop WMC, Lohuis PJFM, Schreuder WH, Smeele LE, van der Velden LA, Bing Tan I, Onderwater S, Jasperse B, Vogel WV, Al-Mamgani A, Keijser A, van der Noort V, Broeks A, Hooijberg E, Peeper DS, Schumacher TN, Blank CU, de Boer JP, Haanen JBAG, Zuur CL. Vos JL, et al. Among authors: de boer jp. Nat Commun. 2021 Dec 22;12(1):7348. doi: 10.1038/s41467-021-26472-9. Nat Commun. 2021. PMID: 34937871 Free PMC article. Clinical Trial.
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM. Armand P, et al. Among authors: de boer jp. J Clin Oncol. 2018 May 10;36(14):1428-1439. doi: 10.1200/JCO.2017.76.0793. Epub 2018 Mar 27. J Clin Oncol. 2018. PMID: 29584546 Free PMC article. Clinical Trial.
MicroRNA-216a is essential for cardiac angiogenesis.
Juni RP, Kocken JMM, Abreu RC, Ottaviani L, Davalan T, Duygu B, Poels EM, Vasilevich A, Hegenbarth JC, Appari M, Bitsch N, Olieslagers S, Schrijvers DM, Stoll M, Heineke J, de Boer J, de Windt LJ, da Costa Martins PA. Juni RP, et al. Among authors: de boer j. Mol Ther. 2023 Jun 7;31(6):1807-1828. doi: 10.1016/j.ymthe.2023.04.007. Epub 2023 Apr 17. Mol Ther. 2023. PMID: 37073128 Free article.
Inhibition of DHCR24 activates LXRα to ameliorate hepatic steatosis and inflammation.
Zhou E, Ge X, Nakashima H, Li R, van der Zande HJP, Liu C, Li Z, Müller C, Bracher F, Mohammed Y, de Boer JF, Kuipers F, Guigas B, Glass CK, Rensen PCN, Giera M, Wang Y. Zhou E, et al. Among authors: de boer jf. EMBO Mol Med. 2023 Aug 7;15(8):e16845. doi: 10.15252/emmm.202216845. Epub 2023 Jun 26. EMBO Mol Med. 2023. PMID: 37357756 Free PMC article.
Modeling the Mechanical Parameters of Glaucoma.
Vroemen PAMM, Gorgels TGMF, Webers CAB, de Boer J. Vroemen PAMM, et al. Among authors: de boer j. Tissue Eng Part B Rev. 2019 Oct;25(5):412-428. doi: 10.1089/ten.TEB.2019.0044. Epub 2019 Sep 18. Tissue Eng Part B Rev. 2019. PMID: 31088331 Review.
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.
Ansell SM, Bröckelmann PJ, von Keudell G, Lee HJ, Santoro A, Zinzani PL, Collins GP, Cohen JB, de Boer JP, Kuruvilla J, Savage KJ, Trněný M, Provencio M, Jäger U, Willenbacher W, Wen R, Akyol A, Mikita-Geoffroy J, Shipp MA, Engert A, Armand P. Ansell SM, et al. Among authors: de boer jp. Blood Adv. 2023 Oct 24;7(20):6266-6274. doi: 10.1182/bloodadvances.2023010334. Blood Adv. 2023. PMID: 37530622 Free PMC article. Clinical Trial.
Combined glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonism attenuates atherosclerosis severity in APOE*3-Leiden.CETP mice.
van Eenige R, Ying Z, Tramper N, Wiebing V, Siraj Z, de Boer JF, Lambooij JM, Guigas B, Qu H, Coskun T, Boon MR, Rensen PCN, Kooijman S. van Eenige R, et al. Among authors: de boer jf. Atherosclerosis. 2023 May;372:19-31. doi: 10.1016/j.atherosclerosis.2023.03.016. Epub 2023 Mar 28. Atherosclerosis. 2023. PMID: 37015151 Free article.
How Not To Drown in Data: A Guide for Biomaterial Engineers.
Vasilevich AS, Carlier A, de Boer J, Singh S. Vasilevich AS, et al. Among authors: de boer j. Trends Biotechnol. 2017 Aug;35(8):743-755. doi: 10.1016/j.tibtech.2017.05.007. Epub 2017 Jul 7. Trends Biotechnol. 2017. PMID: 28693857 Review.
293 results